Sponsored

Chimeric (ASX:CHM) boosts financial footing, enters $30M placement agreement with L1

2 min read | June 09, 2022 08:40 PM EDT | By Aditi Sarkar

Highlights

  • Chimeric has entered an equity funding placement with L1 Capital for up to AU$30 million.
  • The placement follows the successful raising of AU$14.4 million in a previously completed entitlement offer.
  • The agreement has flexible terms, allowing CHM to conduct external capital raisings as well as enter strategic partnerships or licensing agreements.
  • The Company is rapidly moving forward with a portfolio of four Phase 1 clinical trials.

Chimeric Therapeutics Limited (ASX:CHM) is all set to strengthen its financial position with an equity funding agreement with L1 Capital Global Opportunities Master Fund.

The equity placement agreement between CHM and L1 is for up to AU$30 million. The agreement bolsters the Company’s balance sheet as the Australian leader in cell therapy takes huge strides with a portfolio of four Phase 1 clinical trials.

Also read: A snapshot of Chimeric Therapeutics’ (ASX:CHM) crucial update on CORE-NK Cell Platform

Overview of $30M Equity Placement Agreement   

L1 Capital is an Australia-based, leading global investor with over AU$5 billion in funds under management.

The agreement follows the successful completion of CHM’s entitlement offer in February 2022, which raised AU$14.4 million. The development boosted the Company’s current cash position to approximately AU$23.7 million.

The placement agreement will entail an initial placement of AU$500,000 in ordinary shares at AU$0.10 per share with 15 million unlisted options to be issued within seven days. Moreover, the agreement will include an equity placement facility of up to AU$30 million over 24 months ending 9 June 2024, by way of separate placements. The size of these placements is subject to certain limits.

The options, expiring 31 March 2024, are exercisable at AU$0.255 each.   

Flexibility - The placement agreement has flexible terms, allowing CHM to conduct capital raisings external to the arrangement. The Company is under no obligation to use the facility, and the agreement doesn’t restrict Chimeric from entering into strategic partnerships or licensing agreements.

The flexible agreement will accelerate the rapid development of the company’s three CAR T & NK cell platform technologies.

Shares of Chimeric traded at AU$0.105 on 9 June 2022.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Incorporated (Kalkine Media), Business Number: 720744275BC0001 and is available for personal and non-commercial use only. The advice given by Kalkine Media through its Content is general information only and it does not take into account the user’s personal investment objectives, financial situation and specific needs. Users should make their own enquiries about any investment and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media is not registered as an investment adviser in Canada under either the provincial or territorial Securities Acts. Some of the Content on this website may be sponsored/non-sponsored, as applicable, however, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used in the Content unless stated otherwise. The images/music that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.


Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.